medigraphic.com
ISSN 1561-2988 (Print)

2014, Number 4

<< Back Next >>

Rev Cubana Farm 2014; 48 (4)

Evaluation of combination treatment effect of mangiferin with cisplatin and 5-fluorouracil in CT26.WT and CKO-K1 cells

Rodríguez GJC, Rodeiro GI, Hernández BI, Delgado HR

Language: Spanish
References: 21
Page: 658-671
PDF size: 648.59 Kb.


ABSTRACT

Introduction: mangiferin has several pharmacological properties, but others remain to be deeply explored, such as antitumor activity since it may serve as adjuvant agent in conventional antitumoral chemotherapy in a combined treatment.
Objective: to evaluate the antiproliferative effect of the use of mangiferin alone and in combination with low concentrations of chemotherapeutic agents.
Methods: the CT26.WT mouse colon carcinoma and the CHO-K1 hamster ovary normal cell lines were treated with mangiferin in combination with cisplatin and 5-fluorouracil in several treatment schedules (sequential and simultaneous), at different concentrations and incubation times. The cell viability was evaluated by MTT assay.
Results: mangiferin (1-200 µg/mL) was not cytotoxic in both cell lines. Mangiferin (1-200 µg/mL) for 3h plus cisplatin at not citotoxic concentrations (1 µM and 5 µM) for 72 h in sequential combined treatment showed a significant increase of cell death in CT26.WT, without inducing significant increase of cell death in CHO-K1 cells at low concentrations of both compounds. In the case of combined mangiferina and 5-fluorouracil (0,1 µM and 0,5 µM) treatments, cell death rose in a significant way in simultaneous combined treatments for 72 h whereas sequential combined therapy with 5-fluorouracil for 72 h plus mangiferin for 24 h in CT26.WT cells, a significant rise was not induced in the cell line death of CHO-K1 hamster.
Conclusions: mangiferin in combination with low non cytotoxic concentrations of cisplatin and 5-fluorouracil promotes cell death and increases the cytotoxicity of these chemotherapeutic agents in experimental conditions of this study.


REFERENCES

  1. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al. Cancer Incidence in Five Continents. Vol. X [Internet]; [cited 2013 dic 16]. Lyon, IARC. Disponible en: http://ci5.iarc.fr

  2. Ministerio de Salud Pública. Anuario Estadístico de Salud 2012. División Nacional de Estadística [Internet]. La Habana: MINSAP; 2012 [citado 23 Nov 2013]. Disponible en: http://files.sld.cu/dne/files/2013/04/anuario_2012.pdf

  3. Pritchard JR, Lauffenburger DA, Hemann MT. Understanding resistance to combination chemotherapy. Drug Resist Updat. 2012;15:249-57.

  4. Wang-Gillam A, Craig Lockhart A, Picus J. Advances in Management of Metastatic Colorectal Cancer. In: Lyden D, Welch DR, Psaila B, editors. Cancer Metastasis: biologic basis and therapeutics. New York: Cambridge University Press; 2011. p. 356-68.

  5. Sergent C, Franco N, Chapusot C, Lizard-Nacol S, Isambert N, Correia M, et al. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins. Cancer Chemotherapy Pharmacol. 2002;49:445-52.

  6. Gerhauser C. Cancer chemoprevention and nutri-epigenetics: state of the art and future challenges. Top Curr Chem. 2013;329:73-132.

  7. Izzotti A. Molecular medicine and the development of cancer chemopreventive agents. Ann N Y Acad Sci. 2012;1259:26-32.

  8. Vinod BS, Maliekal TT, Anto RJ. Phytochemicals as chemosensitizers: from molecular mechanism to clinical significance. Antioxid Redox Signal. 2013;18:1307-48.

  9. Vyas A, Syeda K, Ahmad A, Padhye S, Sarkar FH. Perspectives on medicinal properties of mangiferin. Mini Rev Med Chem. 2012;12:412-25.

  10. Matkowski A, Kuśś P, Góralska E, Woźniak D. Mangiferin, a bioactive xanthonoid, not only from mango and not just antioxidant. Mini Rev Med Chem. 2013;13:439-55.

  11. Van Meerloo J, Kaspers GJ. Cell sensitivity assays: the MTT assay. Meth Mol Biol. 2011;731:237-45.

  12. Sarkar A, Sreenivasan Y, Ramesh GT, Manna SK. Beta-D-Glucoside suppresses tumor necrosis factor-induced activation of nuclear transcription factor kappa B but potentiates apoptosis. J Biol Chem. 2004;279:33768-81.

  13. du Plessis-Stomana D, du Preezb JGH, Van de Venter M. Combination treatment with oxaliplatin and mangiferin causes Increased apoptosis and downregulation of NFκB in cancer cell lines. Afr J Tradit Complement Altern Med. 2011;8:177-84.

  14. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kB as the matchmaker. Nat Immunol. 2011;12:715-23.

  15. Nakanishi C, Toi M. Nuclear factor- κB inhibitors as sensitizers to anticancer drugs. Nature Reviews Cancer. 2005;5:297-309.

  16. Li F, Sethi G. Targeting transcription factor NF-kB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 2010;1805:167-80.

  17. Leiro J, Arranza JA, Yanez M, Ubeira FM, Sanmartın ML, Orallo F. Expression profiles of genes involved in the mouse nuclear factor-kappa B signal transduction pathway are modulated by mangiferin. Internat Immunopharmacol. 2004;4:763-78.

  18. Garcia-Rivera D, Delgado R, Bougarne N, Haegeman G, Berghe WV. Gallic acid indanone and mangiferin xanthone are strong determinants of immunosuppressive anti-tumour effects of Mangifera indica L. bark in MDA-MB231 breast cancer cells. Cancer Lett. 2011;305:21-31.

  19. Petak I, Houghton JA, Kopper L. Molecular targeting of cell death signal transduction pathways in cancer. Current Signal Transduct Ther. 2006;1:113-31.

  20. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death, a new approach to cancer therapy. J Clin Invest. 2005;115:2625-32.

  21. Kim HJ, Hawke N, Baldwin AS. NF-ĸB an d IKK as therapeutic targets in cancer. Cell Death Differentiation. 2006;13:738-47.




2020     |     www.medigraphic.com